ReviewCurrent hypertension reports2020
Estrogen and Bisphenol A in Hypertension.
Review in Current hypertension reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 59 citations in OpenAlex.
- Urinary bisphenol levels and blood pressure after soda consumption from cans, PET and glass bottles.Scientific reports · 2025Trial
- Endocrine-Disrupting Chemicals and Hypertension: Mechanisms and Clinical Implications.Journal of cardiovascular development and disease · 2026Review
- 7-O-methylpunctatin is a potential inhibitor of human arachidonate 5-lipoxygenase: molecular and structural insights into anti-atherosclerosis therapeutics.Molecular diversity · 2026Article
- Exposure to bisphenols and phthalates and arterial stiffness in women of reproductive age: a New York City cohort analysis.Environment international · 2026Article
- Pharmacotherapeutic considerations of selective estrogen receptor modulators for vascular protection.Frontiers in pharmacology · 2026Review
- The Effect of Oral Administration of Bisphenol A and AF on Their Deposition in the Body Organs of Growing Pigs and the Relationship to Growth Rate.Animals : an open access journal from MDPI · 2025Article
- Integrated Metagenomic and Metabolomic Analysis of In Vitro Murine Gut Microbial Cultures upon Bisphenol S Exposure.Metabolites · 2024Article
- The pharmaco-epigenetics of hypertension: a focus on microRNA.Molecular and cellular biochemistry · 2024Review
- Beyond reproduction: unraveling the impact of sex hormones on cardiometabolic health.Medical review (2021) · 2024Review
- Article
- Bisphenol A-What Do We Know? A Global or Local Approach at the Public Health Risk Level.International journal of molecular sciences · 2024Review
- Article
- Selective Activation of G Protein-coupled Estrogen Receptor 1 Attenuates Atherosclerosis.Current medicinal chemistry · 2024Review
- Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy.Translational oncology · 2024Review
- CTD tetramers: a new online tool that computationally links curated chemicals, genes, phenotypes, and diseases to inform molecular mechanisms for environmental health.Toxicological sciences : an official journal of the Society of Toxicology · 2023Article
- An Overview of the Health Effects of Bisphenol A from a One Health Perspective.Animals : an open access journal from MDPI · 2023Review
- Toxicological evaluation of bisphenol analogues: preventive measures and therapeutic interventions.RSC advances · 2023Review
- Review
- Estrogen normalizes maternal HFD-induced vascular dysfunction in offspring by regulating ATR.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Maternal urinary OPE metabolite concentrations and blood pressure during pregnancy: The HOME study.Environmental research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCardiovascular disease (CVD) is a non-subsiding disease that remains a leading cause of morbidity and mortality. CVD has been associated with endocrine disruptors, such as bisphenol A (BPA). This review critically summarizes existing findings on BPA and hypertension, with particular attention to genomic, non-genomic, molecular, and cellular mechanisms of action that render BPA as a cardiovascular estrogenic disruptor. RECENT
findingsOwing to its similar estrogenic structure, BPA has been shown to affect various phenotypes that are regulated by the natural hormone, estrogen. Indeed, BPA has been shown to interact with estrogen receptors, located both in the cell membrane and in the cytoplasm/nucleus. Given that estrogen plays an important role in cardiovascular physiology, a contributing role for BPA in CVD would not be unexpected. Existing literature, though limited, established BPA as a source of disruption in cardiovascular health, particularly hypertension. However, effects of BPA are largely dependent on the dose, patient gender, tissue, and developmental stage of the exposed tissue/organ. Accumulating evidence argues for an adverse effect of BPA on blood pressure, with this effect being gender, dose, and time specific. Thus, comprehensive studies which take these factors and other parameters, like epigenetic factors, into account are warranted before a thorough understanding is at hand.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.